BODY AS A WHOLE:
headache, abdominal pain/discomfort, foot pain, pain in extremities, injection site reaction (intravenous Ciprofloxacin).
palpitation, atrial flutter, ventricular ectopy, syncope, hypertension, angina pectoris, myocardial infarction, cardiopulmonary arrest, cerebral thrombosis, phlebitis, tachycardia, migraine, hypotension.
CENTRAL NERVOUS SYSTEM:
restlessness, dizziness, lightheadedness, insomnia, nightmares, hallucinations, manic reaction, irritability, tremor, ataxia, convulsive seizures, lethargy, drowsiness, weakness, malaise, anorexia, phobia, depersonalization, depression, paresthesia, abnormal gait, grand mal convulsion.
painful oral mucosa, oral candidiasis, dysphagia, intestinal perforation, gastrointestinal bleeding, cholestatic jaundice, hepatitis.
amylase increase, lipase increase.
arthralgia or back pain, joint stiffness, achiness, neck or chest pain, flare up of gout.
nephritis, interstitial nephritis, renal failure, polyuria, urinary retention, urethral bleeding, vaginitis, acidosis, breast pain.
dyspnea, epistaxis, laryngeal or pulmonary edema, hiccough, hemoptysis, bronchospasm, pulmonary embolism.
allergic reaction, pruritus, urticaria, photosensitivity/phototoxicity reaction, flushing, fever, chills, angioedema, edema of the face, neck, lips, conjunctivae or hands, cutaneous candidiasis, hyperpigmentation, erythema nodosum, sweating.
blurred vision, disturbed vision (change in color perception, overbrightness of lights), decreased visual acuity, diplopia, eye pain, tinnitus, hearing loss, bad taste, chromatopsia.
In several instances nausea, vomiting, tremor, irritability, or palpitation were judged by investigators to be related to elevated serum levels of theophylline possibly as a result of drug interaction with Ciprofloxacin. In randomized, double-blind controlled clinical trials comparing Ciprofloxacin tablets (500 mg twice daily) to cefuroxime axetil (250 mg - 500 mg twice daily) and to clarithromycin (500 mg twice daily) in patients with respiratory tract infections, Ciprofloxacin demonstrated a CNS adverse event profile comparable to the control drugs.